Maxing Ergao Powder enters veterinary manufacturing as a fine milled API with a certificate of analysis specifying loss on drying, particle size distribution, heavy metals, and microbial limits. Each downstream dosage route begins with a forced screening step through a 0.5 mm conical mill to break agglomerates before blend assembly. The powder exhibits hygroscopic behaviour at relative humidity above 60%, which requires room dehumidification to 35–45% RH for dry processing operations. Without pre-conditioning, the material’s bulk density and flowability shift across batches, producing weight variation in tablet presses and capsule fillers. The processing windows for tablet granulation, direct compression, injectable aseptic compounding, premix dilution, capsule filling, oral solution filtration, and granulated top-dress powders are described below.

The milled API is pre-blended with microcrystalline cellulose, sodium starch glycolate, and copovidone at a drug load of 5–30 wt% in a bin blender for 10 minutes before charging into a top-spray fluid bed granulator. Aqueous binder solution is sprayed at a rate of 20–50 g/min per 100 kg batch while inlet air temperature is held between 60°C and 70°C. The granulation endpoint is controlled by dew point and product temperature rather than time alone, with a target granule moisture of 1.5–2.5% after tray drying at 45°C. The dried granulate is sieved through a 1.0 mm oscillating granulator; oversize material is returned to the mill at low speed to avoid generating excessive fines below 75 µm, which increase compression weight variation. A final pre-compression blend includes 0.5–1.0 wt% magnesium stearate, blended for exactly 3 minutes, because longer lubrication at high shear reduces tablet tensile strength. Compression on a rotary tablet press fitted with 12 mm round tooling is controlled to produce compact hardness of 6–8 kp and friability below 1.0% after 100 rotations. Tablet core disintegration in water at 37°C is measured by Ph. Eur. 2.9.1 or USP <701>; the specification is set below 15 minutes to avoid delayed release in target species. If the product requires film coating, hydroxypropyl methylcellulose-based dispersions are applied at 50–60°C inlet temperature and 2.0–3.0% weight gain; coating pans are operated with negative pressure to prevent edge wear and logo bridging. Release testing includes uniformity of dosage units per Ph. Eur. 2.9.40 or USP <905>, dissolution via Ph. Eur. 2.9.3 Apparatus II at 50 rpm, and microbial quality per Ph. Eur. 5.1.4. For this specific herbal powder, wet granulation is selected when the dose weight exceeds 300 mg because direct compression blends become insensitive to flow changes.

When Direct Compression Replaces Wet Granulation for Heat-Labile Veterinary Granules

Direct compression of Maxing Ergao Powder is selected only after a compaction simulator has confirmed the API’s yield pressure and strain-rate sensitivity under compression forces of 8–15 kN. The milled powder is blended with spray-dried lactose and crospovidone; the lactose content is adjusted in 5 wt% increments until the blend reaches a compressibility index below 20% by USP <1174> or Ph. Eur. 2.9.34. Prior to tableting, the blender is charged to 50–70% of its rated capacity to maintain mass flow and to avoid dead zones in the hopper. Tablet press speed is limited to 20–35 rpm for single-station tooling because the powder’s elastic recovery after compression can generate capping in the die ejection stage. The tablet thickness is monitored continuously with a sampling interval of 15 minutes; weight variation across a 10-minute run is held within ±5.0% of target weight. Published data for this specific configuration at production scale is limited; pilot trials with a compaction simulator should define the minimum compression dwell time required to avoid lamination. If the API is sensitive to moisture above 60% RH, a dry-coating step is omitted and the cores are packaged in aluminium foil blisters with desiccant. The direct compression route is not recommended for drug loads above 25 wt% because the cohesive nature of the powder reduces flow and increases sticking to upper punch faces.

Before aseptic compounding begins, the API powder is tested for bacterial endotoxins by Ph. Eur. 2.6.14 or USP <85> with an acceptance limit derived from the maximum daily dose and target species weight, usually not exceeding 0.5 EU/mg for large-animal injectables. The raw powder is dissolved in water for injection at a concentration of 1.0–10.0 wt% in a closed stainless steel reactor with a bottom-mounted magnetic stirrer operating at 200 rpm; dissolution is complete within 20–40 minutes at 25–35°C. The solution is adjusted to pH 5.5–7.5 with 0.1 M hydrochloric acid or sodium hydroxide under continuous pH monitoring, because the herbal-derived matrix may release buffering components that shift pH by up to 0.8 units within 24 hours. If the API is not freely soluble at low temperature, a co-solvent system containing 10–30% propylene glycol or glycofurol is used, but the final osmolality is maintained between 280 mOsm/kg and 320 mOsm/kg for isotonicity. The bulk solution is pre-filtered through a 0.45 µm polyethersulfone membrane, then sterile-filtered through two 0.22 µm filters in series; the differential pressure across the sterilising filter is monitored and must not exceed 15 psi during the filling campaign. Filled vials are terminally sterilised only if the API is thermostable at 121°C for 15 minutes; otherwise, the process is aseptic and the lyophilised cake is produced by freezing at -40°C in a freeze dryer with a chamber pressure of 0.1–0.25 mbar. Release tests include sterility per Ph. Eur. 2.6.1 or USP <71>, particulate contamination per USP <788> and Ph. Eur. 2.9.19, and visible particles under light inspection with a 100% automated check. A key operational boundary is terminal sterilisation: if the product is autoclaved, the pH must remain within the approved range because hydrolysis may generate aglycone degradation products; if lyophilised, the reconstitution time is tested and the residual moisture is controlled below 1.0% by Karl Fischer titration.

Premix Homogeneity Test Standards and Segregation Mechanisms

A premix line processing Maxing Ergao Powder at 0.5–2.0 wt% addition level in a 500 kg ribbon blender requires geometric dilution before final mixing. The concentrated pre-blend is prepared by passing the API through a 0.25 mm sieve and blending with corn starch or lactose in a 1:10 ratio for 10 minutes; this pre-blend is then combined with the remaining carrier in three stages. Ribbon blender speed is set between 20 rpm and 30 rpm, and mixing time is validated by sampling at 10 positions across the blender using a thief sampler. Blend uniformity is considered acceptable when the relative standard deviation of the marker compound across all samples is ≤5.0% and the mean assay is within 90.0–110.0% of the target; this mirrors the in-process control expectations of 21 CFR 211.110(a). After discharge, the premix is packaged in 25 kg valve bags with a moisture barrier liner; storage humidity above 60% promotes particle agglomeration, which subsequently generates segregation during bulk transport. Terminal analytical work includes loss on drying by Ph. Eur. 2.2.32 and a screen analysis with a 0.3 mm sieve to detect dose-containing particles above 0.3 mm that may fail to disperse in feed. The premix is not sterilised; the microbial limits for premixes are set according to the target animal species and may include absence of Salmonella in 25 g per Ph. Eur. 2.6.13. If the premix is later diluted in feed at the farm, the coefficient of variation after field mixing often rises to 10–15% because of mobile auger equipment, so the initial blend uniformity must be tighter than the theoretical feed label claim.

For hard gelatin capsule filling, the API is pre-blended with lactose monohydrate and magnesium stearate in a V-blender equipped with an intensifier bar operating at 1,500 rpm for 10 minutes. The batch is transferred to a tamping pin capsule filling machine with 0.5 g target fill weight for a size 1 capsule; pin compaction speed is reduced to 5–10 strokes/min because the herbal powder has low bulk density and generates dust during high-speed filling. The powder bed depth in the dosator nose is monitored to avoid excessive compaction, which leads to delayed capsule disintegration in gastric fluid. The filled capsules are polished with sodium chloride-free polishing agents to prevent surface residue; metal detection is set to reject capsules with ferrous particles above 0.5 mm. Capsule weight variation is controlled by weighing every 15 minutes; the acceptance range is ±7.5% from the mean weight per USP <905> for capsules. Dissolution is tested by Ph. Eur. 2.9.3 Apparatus II with 900 mL of 0.1 M hydrochloric acid at 37°C and 50 rpm; the release criterion is Q ≥80% at 60 minutes unless a veterinary-specific monograph directs otherwise. Because the capsule shell is gelatin-based, the process room is maintained at 40% RH or below to prevent the shell from becoming brittle or tacky. If the product is intended for dogs or cats, the capsule may be opened and the granulate sprinkled on food; in that case, the blend includes a palatability-neutral carrier and the API is protected from light by amber shell or carton. The final package includes desiccant canisters and is sealed with a tamper-evident film.

What Viscosity Threshold Controls Oral Solution Filtration?

Filtration of oral solutions containing Maxing Ergao Powder is limited by viscosity rather than by API particle size after the powder has fully dissolved or dispersed. The bulk oral vehicle is prepared with purified water, 0.1–0.2 wt% sodium carboxymethylcellulose as a suspending agent, and 0.05–0.1 wt% potassium sorbate as a preservative. Viscosity is measured by a rotational viscometer at 25°C with spindle speed 60 rpm; if the viscosity exceeds 50 mPa·s, the depth filter load increases and the filling pump may cavitate. The solution is first passed through a 75 µm nylon bag filter, then through a 10 µm polypropylene cartridge filter at a flow rate of 1.0–2.0 L/min. For continuous drinking water medication, the stock solution is diluted through a venturi proportioner at a ratio of 1:100 or 1:200, and the final solution is exposed to pH 6.0–8.0 water in the drinking line for up to 12 hours. Stability in diluted form is tested by high-performance liquid chromatography at 0, 6, and 12 hours; the limit for marker compound loss is set at 10% of initial. Because the powder may contain water-soluble polysaccharides, bacterial growth in the drinking water system is managed by cleaning with a 3% hydrogen peroxide solution between flocks and by monitoring heterotrophic plate counts below 100 CFU/mL. The product is packaged in amber high-density polyethylene bottles with polypropylene caps and induction-sealed aluminium foil; the oral solution is stored below 25°C and used within 28 days after first opening, unless a preservative efficacy test under Ph. Eur. 5.1.3 supports a longer in-use period.

Granulation for feed top-dressing differs from tableting granulation because the particle size is matched to the animal’s voluntary intake and the emptying angle of the scoop or pump. The API is wet-massed with maltodextrin and microcrystalline cellulose in a high-shear granulator at an impeller speed of 150–300 rpm and a chopper speed of 1,500 rpm; the wet mass is then extruded through a 0.8 mm screen and spheronised at 600–800 rpm in a spheroniser for 2–5 minutes to produce round pellets with a diameter of 0.6–1.0 mm. The pellets are dried in a fluid bed dryer at 55°C to a final moisture content of 2.0–3.0% and then coated with a thin layer of hydroxypropyl methylcellulose to reduce dust and mask any bitter taste. The product is filled into 50 g or 100 g sachets with a fill weight tolerance of ±5.0%, and the sachet is sealed under vacuum to prevent oxidative degradation. The granules are administered by top-dressing on feed or by mixing into a small amount of wet feed; therefore, the granule dispersion time in 37°C water is controlled below 5 minutes by adjusting the amount of microcrystalline cellulose and the spheronisation time. Release testing includes friability below 1.0% after 100 rotations, loss on drying by Ph. Eur. 2.2.32, and microbial quality per Ph. Eur. 5.1.4. If the product is intended for multi-species use, the label must state the withdrawal period and the species-specific dosing interval, and the granule size is selected to prevent selective feeding by one group. This top-dressing format is not interchangeable with medicated premix; the carrier system contains higher levels of binder and is not designed for extensive dilution in feed.